



1639

Attorney Docket No. 9233-8DV2

PATENT

TECH CENTER 1600/2900

FEB 21 2003

RECEIVED

196
203
3.4.3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Ekwuribe et al.

Serial No.: 09/430,735

Filed: October 29, 1999

For: *METHODS FOR INDUCING ANALGESIA*

Group Art Unit: 1639

Examiner: Cesla, B. M.

Date: February 10, 2003

Commissioner for Patents
Washington, DC 20231

AMENDMENT

Sir:

Responsive to the Notice to Comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures (dated January 9, 2003), please reconsider this application in view of the following amendment and remarks.

Applicants submit herewith a substitute computer readable form (CRF) copy and a substitute paper copy of the "Sequence Listing" in order to comply with the requirements for nucleotide and/or amino acid sequence disclosures as set forth in 37 C.F.R. 1.821-1.825.

In the Specification:

sub 61 Please delete pages 1-20 of the sequence listing included in the Amendment mailed February 20, 2001. Please insert pages 1-24 of the enclosed substitute sequence listing after the claims.

915. 24 28
Please replace the paragraph beginning on page ~~23~~, line ~~12~~ with the following paragraph:

62 --(Twice amended) In another aspect, the therapeutic peptide of the amphiphilic drug-oligomer conjugates are as described in United States Patent 5,641,861, which is incorporated herein by reference, so long as any of such peptides contains a lysine residue. Exemplary peptides described therein include: Ac-Phe-Arg-Trp-Trp-Tyr-Lys—NH₂ (SEQ ID NO:4);